Latest News of CYTK
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
A recent article highlights Cytokinetics Inc. as a promising small-cap stock for investment. It discusses the impact of interest rate cuts on small and mid-cap stocks and provides insights from expert...
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo Finance
Cytokinetics, Inc. shared positive results from the Phase 1 study of CK-4021586 at a medical conference. The study successfully evaluated safety, tolerability, and pharmacokinetics of CK-586, a drug b...
Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds?
A compilation of the 12 Best Biotech Stocks To Invest In According To Hedge Funds includes Cytokinetics, Inc. (NASDAQ:CYTK). The biotech industry is forecasted to grow significantly, with AI-driven dr...
-
Investors in Cytokinetics (NASDAQ:CYTK) have seen incredible returns of 381% over the past five years
By Yahoo! Finance | 3 months agoLong term investing in great businesses like Cytokinetics (NASDAQ:CYTK) can lead to significant share price growth, with a 381% gain in the last five years. Despite not being profitable, its 6.7% annu...
-
Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
By Yahoo! Finance | 3 months agoCytokinetics Inc is a biopharmaceutical company focused on developing therapeutics for muscle-related diseases. Insider Fady Malik sold 131,323 shares, indicating 42 sells and no buys in the past year...
-
Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK)
By Yahoo! Finance | 4 months agoCytokinetics Inc is a biopharmaceutical company focusing on developing muscle-modulating therapeutics. Recent insider selling trends and stock valuation indicate potential overvaluation. Investors may...
-
Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)
By Yahoo! Finance | 4 months agoOn June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), sold 5,000 shares at $52.55 per share, totaling $262,750. The insider now holds 20,600 shares....
-
Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development
By Yahoo! Finance | 4 months agoFady Malik, Executive VP at Cytokinetics Inc, sold 7,788 shares on June 11, 2024, bringing his total to 135,004 shares. The company focuses on developing muscle function modulating therapeutics....